REACNF Co., Ltd. has signed a technical agreement with SANG-A PHARMACEUTICAL ALCO., LTD. This technical agreement aims for technical exchange and strategic collaboration in the wide range of medical life and eco-friendly bio fields.
On July 08, 2021, REACNF Co., Ltd. and the SANG-A PHARMACEUTICAL ALCO., LTD. Research Center signed a technical agreement for the development of medical materials using algae nanocellulose. SANG-A PHARMACEUTICAL ALCO., LTD. Research Center, REACNF Co., Ltd. Officials attended. 
On the 8th, SANG-A PHARMACEUTICAL ALCO., LTD. Research Center in North Gyeongsang Province signed an agreement with Kim Min-sun, head of the institute, and Han Jae-hyun, CEO of REACNF.
SANG-A PHARMACEUTICAL ALCO., LTD. is an affiliate of the SANG-A PHARMACEUTICAL ALCO., LTD. Group, and has excellent technology and cooperation with OOP (Object Oriented Processing), which organizes and operates research centers.
REACNF Co., Ltd. is a company that develops eco-friendly biofibers and nanocellulose (CNF) and developed the first algae nanocellulose (CNF) using agaris in Korea, and is currently registered as a research company of Gimhae Innopolis and is researching and developing nanofiber technology for medical materials.
Han Jae-hyun, CEO of REACNF Co., Ltd., said, "SANG-A PHARMACEUTICAL ALCO., LTD., and REACNF Co., Ltd., a seaweed nanocellulose research and development company. It aims for technical exchange and strategic cooperation in the wide range of medical life and eco-friendly bio fields. Through the agreement, we will discover and review the potential technologies of the two companies to achieve co-prosperity with the development of new materials and complete the development of eco-friendly and harmless medical materials for the human body," he said.
ⓒREACNF Co., Ltd.
|
